RECOTHROM Drug Profile

Summary for Tradename: RECOTHROM

High Confidence Patents:	4
Applicants:	1
BLAs:	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for RECOTHROM Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for RECOTHROM Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Baxter Healthcare Corporation	RECOTHROM	thrombin topical (recombinant)	For Solution	125248	5,476,777	2012-12-30	DrugPatentWatch analysis and company disclosures
Baxter Healthcare Corporation	RECOTHROM	thrombin topical (recombinant)	For Solution	125248	5,502,034	2015-06-05	DrugPatentWatch analysis and company disclosures
Baxter Healthcare Corporation	RECOTHROM	thrombin topical (recombinant)	For Solution	125248	5,527,692	2015-06-05	DrugPatentWatch analysis and company disclosures
Baxter Healthcare Corporation	RECOTHROM	thrombin topical (recombinant)	For Solution	125248	8,071,090	2028-06-13	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for RECOTHROM Derived from Patent Text Search

No patents found based on company disclosures

International Patents for RECOTHROM

Country	Patent Number	Estimated Expiration
Canada	2687968
World Intellectual Property Organization (WIPO)	2008157304
European Patent Office	2167041
Israel	202306
Japan	2010529997
Spain	2397234
Australia	2008266094

Market Dynamics and Financial Trajectory for RECOTHROM

Last updated: February 20, 2026

What is RECOTHROM and its approved indications?

RECOTHROM (thrombin topical) is a human plasma-derived biologic indicated for topical hemostasis during surgical procedures. It is approved by the U.S. Food and Drug Administration (FDA) for use in controlling bleeding in hemostasis during surgery, particularly in cardiovascular, neurological, and other surgical procedures.

Approved in 2012, RECOTHROM is manufactured by ZymoGenetics, a Bristol-Myers Squibb company. It is distinct from other topical thrombins due to its recombinant form, although marketed as a plasma-derived product earlier.

How does RECOTHROM's market positioning compare to competitors?

RECOTHROM operates within a niche market of topical hemostatic agents. Its primary competitors include:

• Floseal (Hemoscope): A gelatin-thrombin matrix used for local bleeding control.
• Surgiflo (Ethicon): Fibrin sealant composed of fibrinogen and thrombin.
• Evicel (Ethicon): Fibrin sealant derived from human plasma.

RECOTHROM's advantages include human recombinant production, reducing the risk of disease transmission and immunogenic responses compared to plasma-derived products.

Market share and adoption

In the U.S., RECOTHROM's market share remains modest, estimated at less than 10% of the total topical hemostatic agents segment. It faces limited penetration due to:

• Lack of extensive brand recognition outside specialized surgical centers.
• Pricing strategies relative to plasma-derived and fibrin sealants.
• Preference for established products with wider adoption in certain specialties.

What are the revenue trends and financial projections?

Past revenue performance

Bristol-Myers Squibb (BMS) reported minimal revenue specifically attributable to RECOTHROM, considering its niche status and limited sales volume. Exact figures are not publicly available due to confidentiality and product revenue being part of broader segment reports.

Estimated market size

Global surgical hemostats market was valued at approximately USD 2.5 billion in 2020, with topical agents representing a significant subset. RECOTHROM's addressable market in the U.S. is estimated at USD 150–200 million, based on the number of surgeries requiring topical hemostasis and physician preferences.

Revenue projections

Assuming a conservative 1-2% market share growth over the next five years, driven by increased surgical volume and adoption, RECOTHROM could generate USD 3–5 million in annual revenue by 2025. This projection considers:

• Increasing overall surgical procedures.
• Efforts to expand indications.
• Reimbursement improvements in certain markets.

However, market penetration remains limited by competitors' stronghold and product awareness barriers.

What regulatory and market force factors influence RECOTHROM’s prospects?

Regulatory landscape

The FDA regulates RECOTHROM as a Class III biologic. In 2019, the FDA approved a special use designation for certain uses, but no significant recent regulatory changes have announced expansion or new indications.

Reimbursement policies

Reimbursement hinges on procedure codes for surgical hemostasis. Currently, RECOTHROM benefits from existing operative procedure codes for topical hemostats but faces challenges due to reimbursement rates aligned with other, more established products.

Market drivers

• Increase in cardiovascular and complex surgeries.
• Growing preference for recombinant biologics over plasma-derived products.
• Emphasis on reducing infection risks and immunogenicity in surgical hemostasis.

Challenges

• Limited awareness among surgeons.
• Competition from fibrin sealants with broader indications.
• Cost considerations, as recombinant products tend to be priced higher.

How do macroeconomic and healthcare trends impact RECOTHROM?

The rise in surgery volumes, especially elective procedures, sustains stable demand for hemostatic agents. Healthcare cost pressures favor products with proven safety profiles and competitive pricing. The shift toward minimally invasive procedures enhances the need for effective topical hemostats.

What is the strategic outlook?

Continued investment in clinical studies demonstrating efficacy and safety could expand RECOTHROM’s indications. Collaborations with surgical device companies might improve distribution. However, unless product differentiation or cost advantages emerge, market growth remains constrained.

Key Financial and Market Conclusions

• Revenue: Limited, with modest growth potential.
• Market share: Under 10%, with possible incremental increases.
• Growth drivers: Surgical volume increases, recombinant biologic preference.
• Market risks: Intense competition, reimbursement challenges, low brand visibility.

Key Takeaways

• RECOTHROM is a niche, recombinant human thrombin product approved for surgical hemostasis.
• Its market penetration remains limited relative to longstanding fibrin sealants and other hemostatic agents.
• Revenue forecasts suggest modest growth, constrained by competitive and awareness factors.
• Regulatory environment aligns with standard biologic approvals; no recent significant changes.
• Market drivers include increasing surgical procedures and preference for recombinant biologics, but price competition and product familiarity pose risks.

FAQs

1. What differentiates RECOTHROM from other topical thrombins?
   It is produced recombinantly, which reduces disease transmission risk compared to plasma-derived thrombins.

2. What is RECOTHROM’s primary market?
   The U.S. surgical hemostasis segment, especially cardiovascular and neurological surgeries.

3. Has RECOTHROM received any recent FDA approvals for new indications?
   No, it remains approved for their original indications since 2012.

4. What factors limit RECOTHROM’s market expansion?
   Competition from fibrin sealants, lack of widespread surgeon awareness, and pricing strategies.

5. What is the long-term sales outlook for RECOTHROM?
   Modest growth is expected unless new indications are approved or marketing strategies significantly improve adoption.

---

References

1. FDA. (2012). RECOTHROM (Thrombin Topical) Prescribing Information. U.S. Food and Drug Administration.
2. MarketsandMarkets. (2021). Surgical Hemostats Market Report.
3. Bristol-Myers Squibb Company. (2022). Annual Report.
4. Statista Research. (2022). Global Surgical Hemostats Market Size.
5. industry reports, company disclosures, and market analyses.